Supplementary Figure 1 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates
Key Points
Key points are not available for this paper at this time.
Abstract
Supplementary Figure 1. Change in sum of longest tumor diameters across response assessments in liposarcoma and UPS/Other cohorts.
Supplementary Figure 1 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates | Synapse